Anti-RHD / CD240d (LFB Anti-RhD) is a polyclonal IgG antibody specificly targeting RhD (rhesus D). It is used in the treatment of fetal hemolytic disease. MW :147.46 KD.

Anti-RHD / CD240d (LFB Anti-RhD) is a polyclonal IgG antibody specificly targeting RhD (rhesus D). It is used in the treatment of fetal hemolytic disease. MW :147.46 KD.

Anti-RHD / CD240d (LFB Anti-RhD) is a polyclonal IgG antibody specificly targeting RhD (rhesus D). It is used in the treatment of fetal hemolytic disease. MW :147.46 KD.

Anti-ROBO1 (Asclepius Technology patent anti-Robo1 CAR) is a bispecific antigen-binding construct targeting ROBO1, with a single-chain variable region antibody fragment ScFV binding to the surface antigen of immune cells and a Slit2D2 protein fragment binding to the surface antigen Robo1 of tumour cells.MW: 145.5 kD.

Anti-ROBO1 (Asclepius Technology patent anti-Robo1 CAR) is a bispecific antigen-binding construct targeting ROBO1, with a single-chain variable region antibody fragment ScFV binding to the surface antigen of immune cells and a Slit2D2 protein fragment binding to the surface antigen Robo1 of tumour cells.MW: 145.5 kD.

Anti-ROBO1 (Asclepius Technology patent anti-Robo1 CAR) is a bispecific antigen-binding construct targeting ROBO1, with a single-chain variable region antibody fragment ScFV binding to the surface antigen of immune cells and a Slit2D2 protein fragment binding to the surface antigen Robo1 of tumour cells.MW: 145.5 kD.

Anti-RSPO1 is a monoclonal antibodies against R-spondin1 gene (RSPO1) with potential anti-tumor activity . MW: 150 KD.

Anti-RSPO1 is a monoclonal antibodies against R-spondin1 gene (RSPO1) with potential anti-tumor activity . MW: 150 KD.

Anti-RSPO1 is a monoclonal antibodies against R-spondin1 gene (RSPO1) with potential anti-tumor activity . MW: 150 KD.

Anti-RTN4 / NOGO is an antibody acting against anti-RTN4. MW : 145.4 kD.

Anti-RTN4 / NOGO is an antibody acting against anti-RTN4. MW : 145.4 kD.

Anti-RTN4 / NOGO is an antibody acting against anti-RTN4. MW : 145.4 kD.

Anti-S100A4 (LK-1) is a monoclonal antibody targeting the small Ca-binding protein, S100A4. It can be used in development of an efficient anti-metastatic therapy in various cancers. MW :145.04 KD.

Anti-S100A4 (LK-1) is a monoclonal antibody targeting the small Ca-binding protein, S100A4. It can be used in development of an efficient anti-metastatic therapy in various cancers. MW :145.04 KD.

Anti-S100A4 (LK-1) is a monoclonal antibody targeting the small Ca-binding protein, S100A4. It can be used in development of an efficient anti-metastatic therapy in various cancers. MW :145.04 KD.

Anti-SCFR / c-Kit / CD117 is a humanized monoclonal antibody against the stem cell factor receptor c-Kit (SCFR) with potential antineoplastic activity. MW : 150 kD.

Anti-SCFR / c-Kit / CD117 is a humanized monoclonal antibody against the stem cell factor receptor c-Kit (SCFR) with potential antineoplastic activity. MW : 150 kD.

Anti-SCFR / c-Kit / CD117 is a humanized monoclonal antibody against the stem cell factor receptor c-Kit (SCFR) with potential antineoplastic activity. MW : 150 kD.

Anti-SCFR / c-Kit / CD117 (CDX-0158) is a humanized immunoglobulin (Ig) G1 monoclonal antibody against the stem cell factor receptor c-Kit (SCFR; KIT; CD117), with potential antineoplastic and anti-allergic activities. CDX‐0159 inhibits SCF‐dependent KIT and mast cell activation. MW: 145.1 kD.

Anti-SCFR / c-Kit / CD117 (CDX-0158) is a humanized immunoglobulin (Ig) G1 monoclonal antibody against the stem cell factor receptor c-Kit (SCFR; KIT; CD117), with potential antineoplastic and anti-allergic activities. CDX‐0159 inhibits SCF‐dependent KIT and mast cell activation. MW: 145.1 kD.

Anti-SCFR / c-Kit / CD117 (CDX-0158) is a humanized immunoglobulin (Ig) G1 monoclonal antibody against the stem cell factor receptor c-Kit (SCFR; KIT; CD117), with potential antineoplastic and anti-allergic activities. CDX‐0159 inhibits SCF‐dependent KIT and mast cell activation. MW: 145.1 kD.

Anti-SCN11a / Nav1.9 is a monoclonal anti-Nav1.9 (SCN11A) antibody used in antigen-specific immunodetection in biological samples. MW: 143.94 KD.

Anti-SCN11a / Nav1.9 is a monoclonal anti-Nav1.9 (SCN11A) antibody used in antigen-specific immunodetection in biological samples. MW: 143.94 KD.

Anti-SCN11a / Nav1.9 is a monoclonal anti-Nav1.9 (SCN11A) antibody used in antigen-specific immunodetection in biological samples. MW: 143.94 KD.

Anti-SCN9a / Nav1.7 is a fully human antibody that binds to human Nav1.7 (hNav1.7, SCN9a) with the potential to treat acute or chronic pain conditions or inflammatory conditions. MW: 145.72 KD.

Anti-SCN9a / Nav1.7 is a fully human antibody that binds to human Nav1.7 (hNav1.7, SCN9a) with the potential to treat acute or chronic pain conditions or inflammatory conditions. MW: 145.72 KD.

Anti-SCN9a / Nav1.7 is a fully human antibody that binds to human Nav1.7 (hNav1.7, SCN9a) with the potential to treat acute or chronic pain conditions or inflammatory conditions. MW: 145.72 KD.

Anti-SERPINE1 is a monoclonal antibody that specifically binds to Plasminogen Activator Inhibitor Type-1 (PAI-1, SERPINE1) with the potential to be used in cardiovascular diseases. MW: 145.72 KD.

Anti-SERPINE1 is a monoclonal antibody that specifically binds to Plasminogen Activator Inhibitor Type-1 (PAI-1, SERPINE1) with the potential to be used in cardiovascular diseases. MW: 145.72 KD.

Anti-SERPINE1 is a monoclonal antibody that specifically binds to Plasminogen Activator Inhibitor Type-1 (PAI-1, SERPINE1) with the potential to be used in cardiovascular diseases. MW: 145.72 KD.

Anti-Sialyl-Lewis A is a human monoclonal antibody against the carbohydrate antigen sialyl-Lewis A (carbohydrate antigen 19-9; CA19-9) with potential antineoplastic activity.MW : 145.5 kD.

Anti-Sialyl-Lewis A is a human monoclonal antibody against the carbohydrate antigen sialyl-Lewis A (carbohydrate antigen 19-9; CA19-9) with potential antineoplastic activity.MW : 145.5 kD.

Anti-Sialyl-Lewis A is a human monoclonal antibody against the carbohydrate antigen sialyl-Lewis A (carbohydrate antigen 19-9; CA19-9) with potential antineoplastic activity.MW : 145.5 kD.

Anti-Siglec-15 / CD33L3 (AB-25E9) is a humanized monoclonal antibody targeting sialic acid-binding immunoglobulin-like lectin 15 (Siglec-15). It may have potential as an anti-resorptive therapy for osteoporosis. MW :150 KD.

Anti-Siglec-15 / CD33L3 (AB-25E9) is a humanized monoclonal antibody targeting sialic acid-binding immunoglobulin-like lectin 15 (Siglec-15). It may have potential as an anti-resorptive therapy for osteoporosis. MW :150 KD.

Anti-Siglec-15 / CD33L3 (AB-25E9) is a humanized monoclonal antibody targeting sialic acid-binding immunoglobulin-like lectin 15 (Siglec-15). It may have potential as an anti-resorptive therapy for osteoporosis. MW :150 KD.

Anti-Siglec-15 / CD33L3 (NC318) is a monoclonal antibody targeting Siglec-15. It can be used as a novel immune suppressor and a potential target for normalization cancer immunotherapy. MW :146.98 KD.

Anti-Siglec-15 / CD33L3 (NC318) is a monoclonal antibody targeting Siglec-15. It can be used as a novel immune suppressor and a potential target for normalization cancer immunotherapy. MW :146.98 KD.

Anti-Siglec-15 / CD33L3 (NC318) is a monoclonal antibody targeting Siglec-15. It can be used as a novel immune suppressor and a potential target for normalization cancer immunotherapy. MW :146.98 KD.

Anti-Siglec-2 / CD22 (NCI m971) is a humanized monoclonal antibody targeting CD22, a Siglec family lectin present on B cells. It is used in treatment of acute lymphoblastic leukemia (ALL). MW :146.64 KD.

Anti-Siglec-2 / CD22 (NCI m971) is a humanized monoclonal antibody targeting CD22, a Siglec family lectin present on B cells. It is used in treatment of acute lymphoblastic leukemia (ALL). MW :146.64 KD.

Anti-Siglec-2 / CD22 (NCI m971) is a humanized monoclonal antibody targeting CD22, a Siglec family lectin present on B cells. It is used in treatment of acute lymphoblastic leukemia (ALL). MW :146.64 KD.

Anti-Siglec-2 / CD22 (NCI m972) is a humanized monoclonal antibody targeting CD22, a Siglec family lectin present on B cells. It is a promising novel therapeutics for B-cell acute lymphoblastic leukemia (BCP-ALL). MW :144.3 KD.

Anti-Siglec-2 / CD22 (NCI m972) is a humanized monoclonal antibody targeting CD22, a Siglec family lectin present on B cells. It is a promising novel therapeutics for B-cell acute lymphoblastic leukemia (BCP-ALL). MW :144.3 KD.

Anti-Siglec-2 / CD22 (NCI m972) is a humanized monoclonal antibody targeting CD22, a Siglec family lectin present on B cells. It is a promising novel therapeutics for B-cell acute lymphoblastic leukemia (BCP-ALL). MW :144.3 KD.

Anti-SIRPa / CD172a is an immunoglobulin G1 (IgG1) monoclonal antibody targeting human signal-regulatory protein alpha (SIRPa; CD172a), with potential immune checkpoint inhibitory, phagocytosis-inducing and antineoplastic activities. MW : 147.06 kD.

Anti-SIRPa / CD172a is an immunoglobulin G1 (IgG1) monoclonal antibody targeting human signal-regulatory protein alpha (SIRPa; CD172a), with potential immune checkpoint inhibitory, phagocytosis-inducing and antineoplastic activities. MW : 147.06 kD.

Anti-SIRPa / CD172a is an immunoglobulin G1 (IgG1) monoclonal antibody targeting human signal-regulatory protein alpha (SIRPa; CD172a), with potential immune checkpoint inhibitory, phagocytosis-inducing and antineoplastic activities. MW : 147.06 kD.

Anti-SIRPg is a recombinant human antibody that act againts anti-SIRPG (anti-Signal-Regulatory Protein Gamma). MW : 145.5 KD

Anti-SIRPg is a recombinant human antibody that act againts anti-SIRPG (anti-Signal-Regulatory Protein Gamma). MW : 145.5 KD